ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Glucosamine Improves Non-Alcoholic Fatty Liver Disease Induced by High-Fat and High-Sugar Diet through Regulating Intestinal Barrier Function, Liver Inflammation, and Lipid Metabolism

Li, Feng; Zhang, Zhengyan; Bai, Yan; Che, Qishi; Cao, Hua; Guo, Jiao*; Su, Zhengquan*广东药学院
MOLECULES2023-10DOI: 10.3390/molecules28196918
1被引14阅读
引用收藏
分享

摘要

Non-alcoholic fatty liver disease (NAFLD) is a liver disease syndrome. The prevalence of NAFLD has continued to increase globally, and NAFLD has become a worldwide public health problem. Glucosamine (GLC) is an amino monosaccharide derivative of glucose. GLC has been proven to not only be effective in anti-inflammation applications, but also to modulate the gut microbiota effectively. Therefore, in this study, the therapeutic effect of GLC in the NAFLD context and the mechanisms underlying these effects were explored. Specifically, an NAFLD model was established by feeding mice a high-fat and high-sugar diet (HFHSD), and the HFHSD-fed NAFLD mice were treated with GLC. First, we investigated the effect of treating NAFLD mice with GLC by analyzing serum- and liver-related indicator levels. We found that GLC attenuated insulin resistance and inflammation, increased antioxidant function, and attenuated serum and liver lipid metabolism in the mice. Then, we investigated the mechanism underlying liver lipid metabolism, inflammation, and intestinal barrier function in these mice. We found that GLC can improve liver lipid metabolism and relieve insulin resistance and oxidative stress levels. In addition, GLC treatment increased intestinal barrier function, reduced LPS translocation, and reduced liver inflammation by inhibiting the activation of the LPS/TLR4/NF-kappa B pathway, thereby effectively ameliorating liver lesions in NAFLD mice.

学科与关键词

关键词
non-alcoholic fatty liver diseaseglucosamineinflammationliver lipid metabolismintestinal barrier
相关
加载中…
  • Utilization of Food-Derived β-Glucans to Prevent and Treat Non-Alcoholic Fatty Liver Disease (NAFLD)
    Kei, Nelson; Wong, Vincent Wai Sun; Lauw, Susana; You, Lijun; Cheung, Peter Chi Keung*Foods, 2023, 12(17): 3279.被引 1
  • GOS Ameliorates Nonalcoholic Fatty Liver Disease Induced by High Fat and High Sugar Diet through Lipid Metabolism and Intestinal Microbes
    Qiu, Shuting; Chen, Jiajia; Bai, Yan; He, Jincan; Cao, Hua; Che, Qishi; Guo, Jiao*; Su, Zhengquan*OncoImmunology, 2022, 14(13): 2749.被引 10
  • Marine Chitooligosaccharide Alters Intestinal Flora Structure and Regulates Hepatic Inflammatory Response to Influence Nonalcoholic Fatty Liver Disease
    Feng, Jiayao; Liu, Yongjian; Chen, Jiajia; Bai, Yan; He, Jincan; Cao, Hua; Che, Qishi; Guo, Jiao*; Su, Zhengquan*Marine Drugs, 2022, 20(6): 383.被引 11
查看全部 →

发表信息

论文状态
公开发表
期刊
MOLECULES
发表日期
2023-10
卷期
第 28 卷, 第 19 期
页码
6918
DOI
10.3390/molecules28196918
语言
ENGLISH
成果收录
SCIE
资助标注
Science and Technology Program of Guangzhou, China [202103000089]; Guangdong Demonstration Base for Joint Cultivation of Postgraduates(2023); Science Foundation for Distinguished Young Scholars of Guangdong, China [2020B1515020026]

作者

  • L

    Li, Feng (第一作者)

    guangdong pharmaceut univ · new

  • Z

    Zhang, Zhengyan

    guangdong pharmaceut univ · new

查看全部 7 位作者收起作者
  • B

    Bai, Yan

    guangdong pharmaceut univ

  • C

    Che, Qishi

  • C

    Cao, Hua

    guangdong pharmaceut univ

  • G

    Guo, Jiao (通讯)

    guangdong pharmaceut univ

  • S

    Su, Zhengquan (通讯)

    guangdong pharmaceut univ · new

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417